Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell
[url="]Genmab A/S[/url](Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed tr